Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

Different pearl indices in studies of hormonal contraceptives in the United States: impact of study population.

Gerlinger C, Trussell J, Mellinger U, Merz M, Marr J, Bannemerschult R, Schellschmidt I, Endrikat J.

Contraception. 2014 Aug;90(2):142-6. doi: 10.1016/j.contraception.2014.03.018. Epub 2014 Apr 13.

PMID:
24813941
[PubMed - in process]
Free Article
2.

Effect of a Low-Dose Contraceptive Patch on Efficacy, Bleeding Pattern, and Safety: A 1-Year, Multicenter, Open-Label, Uncontrolled Study.

Wiegratz I, Bassol S, Weisberg E, Mellinger U, Merz M.

Reprod Sci. 2014 Apr 30. [Epub ahead of print]

PMID:
24784719
[PubMed - as supplied by publisher]
3.

Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea.

Petraglia F, Parke S, Serrani M, Mellinger U, Römer T.

Int J Gynaecol Obstet. 2014 Jun;125(3):270-4. doi: 10.1016/j.ijgo.2013.11.017. Epub 2014 Mar 11.

PMID:
24713413
[PubMed - in process]
4.

Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America.

Nelson A, Parke S, Mellinger U, Zampaglione E, Schmidt A.

J Womens Health (Larchmt). 2014 Mar;23(3):204-10. doi: 10.1089/jwh.2013.4320. Epub 2013 Nov 26.

PMID:
24279594
[PubMed - indexed for MEDLINE]
5.

Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction.

Davis SR, Bitzer J, Giraldi A, Palacios S, Parke S, Serrani M, Mellinger U, Nappi RE.

J Sex Med. 2013 Dec;10(12):3069-79. doi: 10.1111/jsm.12310. Epub 2013 Sep 12.

PMID:
24034466
[PubMed - indexed for MEDLINE]
6.

Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.

Macìas G, Merki-Feld GS, Parke S, Mellinger U, Serrani M.

J Obstet Gynaecol. 2013 Aug;33(6):591-6. doi: 10.3109/01443615.2013.800851.

PMID:
23919857
[PubMed - indexed for MEDLINE]
7.

Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe.

Nelson A, Parke S, Makalova D, Serrani M, Palacios S, Mellinger U.

Eur J Contracept Reprod Health Care. 2013 Aug;18(4):264-73. doi: 10.3109/13625187.2013.780202. Epub 2013 May 7.

PMID:
23651474
[PubMed - indexed for MEDLINE]
8.

Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate.

Jensen JT, Parke S, Mellinger U, Serrani M, Mabey RG Jr.

Eur J Contracept Reprod Health Care. 2013 Aug;18(4):274-83. doi: 10.3109/13625187.2013.785516. Epub 2013 May 2.

PMID:
23638631
[PubMed - indexed for MEDLINE]
9.

Estimation of menstrual blood loss volume based on menstrual diary and laboratory data.

Schumacher U, Schumacher J, Mellinger U, Gerlinger C, Wienke A, Endrikat J.

BMC Womens Health. 2012 Aug 20;12:24. doi: 10.1186/1472-6874-12-24.

PMID:
22906181
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women.

Blode H, Zeun S, Parke S, Zimmermann T, Rohde B, Mellinger U, Kunz M.

Contraception. 2012 Oct;86(4):337-44. doi: 10.1016/j.contraception.2012.01.010. Epub 2012 Mar 23.

PMID:
22445438
[PubMed - indexed for MEDLINE]
11.

Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest.

Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M.

Contraception. 2012 Aug;86(2):96-101. doi: 10.1016/j.contraception.2011.11.011. Epub 2012 Jan 10.

PMID:
22240178
[PubMed - indexed for MEDLINE]
12.

Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial.

Fraser IS, Römer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT.

Hum Reprod. 2011 Oct;26(10):2698-708. doi: 10.1093/humrep/der224. Epub 2011 Jul 21.

PMID:
21784734
[PubMed - indexed for MEDLINE]
Free Article
13.

Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest.

Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J.

Eur J Contracept Reprod Health Care. 2011 Aug;16(4):258-69. doi: 10.3109/13625187.2011.591456.

PMID:
21774563
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy.

Wiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Lange E, Mellinger U, Palombo-Kinne E, Kuhl H.

Contraception. 2011 Aug;84(2):133-43. doi: 10.1016/j.contraception.2011.01.002. Epub 2011 Feb 21.

PMID:
21757054
[PubMed - indexed for MEDLINE]
15.

Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Junge W, Mellinger U, Parke S, Serrani M.

Clin Drug Investig. 2011;31(8):573-84. doi: 10.2165/11590220-000000000-00000.

PMID:
21721593
[PubMed - indexed for MEDLINE]
16.

Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.

Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W.

Drugs R D. 2011;11(2):159-70. doi: 10.2165/11591200-000000000-00000.

PMID:
21679006
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.

Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS.

Obstet Gynecol. 2011 Apr;117(4):777-87. doi: 10.1097/AOG.0b013e3182118ac3.

PMID:
21422847
[PubMed - indexed for MEDLINE]
18.

Effects of combined oral contraceptive ethinylestradiol (30 microg) and dienogest (2 mg) on carbohydrate metabolism during 1 year of conventional or extended-cycle use.

Wiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Palombo-Kinne E, Mellinger U, Lange E, Kuhl H.

Horm Metab Res. 2010 May;42(5):358-63. doi: 10.1055/s-0030-1248263. Epub 2010 Mar 8.

PMID:
20213585
[PubMed - indexed for MEDLINE]
19.

Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use.

Wiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Palombo-Kinne E, Mellinger U, Lange E, Kuhl H.

Contraception. 2010 Jan;81(1):57-61. doi: 10.1016/j.contraception.2009.07.011. Epub .

PMID:
20004274
[PubMed - indexed for MEDLINE]
20.

Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.

Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D.

Contraception. 2009 Nov;80(5):436-44. doi: 10.1016/j.contraception.2009.03.018. Epub 2009 May 13.

PMID:
19835717
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk